Clinical trial NCT01840761: Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine
Official title: Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Aneurysm
Keywords: delayed vasospasm,
medicine,
standardization
Lead sponsor: Guangzhou University of Traditional Chinese Medicine
Sponsor class: OTHER
First posted: 2013-04-26
Enrollment: 60
Sex: ALL
Minimum age (years): 14
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Delayed vasospasm (DCVS) is the most serious complication of aneurysmal subarachnoid hemorrhage (aSAH) perioperative period ,the incidence rate up to 30% to 90%, and often can cause severe brain ischemia or brain damage of delayed ischemic and even lead to cerebral infarction, to be the main factor of deadly and severe disability . (aSAH) perioperative delayed vasospasm (CVS) is the bottleneck to restrict the long-term effect. Since there is no standard clinical treatment programs, limiting the advantages and characteristics of traditional Chinese medicine to play.Guangdong Provincial Hospital of TCM is the province's Medical Center encephalopathy, treated 100 brain aneurysm patients each year, more than 80 times craniotomies and surgical interventions , with a rich source of patiengs to carry out the study. In this study, on the basis studies on hemorrhagic stroke of a yin and yang syndrome and comprehensive treatment programe of the State 1995,the 15th research , in accordance with characteristics of the pathophysiology and understanding of cause and pathogenesis in aSAH perioperative period , through expert advice and review of the literature, under the guidance of Liu Maocai who isChinese medicine practitioners of Guangdong province , from diagnosis, diagnosis and treatment,prescription drugs, and other aspects of efficacy evaluation, developmenting a standardized treatment program of delayed CVS after aSAH . To evaluate the efficacy of the standardized program by prospective, randomized,controlled clinical trial,improving the postoperative results, reducting significantly the mortality and morbidity patients with cerebral aneurysms.


Eligibility criteria: Inclusion Criteria:

* Between the ages of 14-80 years old patients;
* Comply with the diagnostic criteria for Chinese and Western medicine;
* Comply with embolization of intracranial aneurysms or cranial aneurysm surgery indications;
* Preoperative Hunt and Hess grade of Ⅰ \~ Ⅳ; The first disease or previous history of stroke but no sequelae;
* Acceptance within 72h onset cranial aneurysm embolization or craniotomy aneurysm surgeon;
* Informed consent;

Exclusion Criteria:

* The age of 14 years of age or in patients over 80 years of age;
* By hypertension, a variety of blood diseases, amyloid angiopathy, cerebral arteritis, cerebral abnormal vascular network (moyamoya disease), brain tumor brain metastases as a result of bleeding;
* Associated with cardiovascular, liver and kidney and hematopoietic system of primary disease, mental illness;
* 72h of onset did not receive cranial aneurysm embolization or craniotomy for aneurysm surgery were;

Primary outcomes:
measure: The incidence of DCVS after aneurysmal postoperative
timeFrame: 3 months
Secondary outcomes:
measure: 1 month, 3 month mortality
timeFrame: 14days,1 month,3 month
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong Provincial Science and Technology Agency
state: Guangdong
Study officials:
References: